From: Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
Variables | HR (95% CI) | P value |
---|---|---|
Gender | ||
 Male | Reference |  |
 Female | 1.634(0.793,3.368) | 0.183 |
ECOG performance | ||
 1 | Reference |  |
 0 | 0.846(0.485,1.474) | 0.555 |
Hepatitis | ||
 Hepatitis B | Reference |  |
 Other | 0.845(0.431,1.656) | 0.624 |
Child–Pugh score | ||
 B | Reference |  |
 A | 1.715(0.415,7.088) | 0.456 |
Age (years) | 0.987(0.961,1.015) | 0.358 |
AST (µmol/L) | 1.004 (0.997,1.010) | 0.262 |
ALT (µmol/L) | 1.006 (0.992, 1.020) | 0.414 |
PLR | 1.002(0.999, 1.006) | 0.244 |
NLR | 0.795(0.653, 0.969) | 0.023 |
Albumin (g/L) | 1.004 (0.913, 1.104) | 0.934 |
TB (µmol/L) | 0.973(0.933,1.015) | 0.200 |
PT (s) | 1.001(0.807,1.241) | 0.991 |
Tumor size | 0.979 (0.862, 1.112) | 0.744 |
BCLC stage | ||
 C | Reference |  |
 B | 0.557(0.299, 1.037) | 0.065 |
Tumor number | ||
  = 1 | Reference |  |
  ≥ 2 | 0.551 (0.299, 1.017) | 0.057 |
α-Fetoprotein level | ||
  ≥ 400 ng/mL | Reference |  |
  < 400 ng/mL | 1.168 (0.643, 2.121) | 0.610 |
Treatment method | ||
 TACE-alone | Reference |  |
 TACE-camrelizumab | 1.206(0.599,2.428) | 0.600 |